Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Oliver Howes, Bernard R Bukala, Katherine Beck
Nature Reviews Neurology (2023) Vol. 20, Iss. 1, pp. 22-35
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 14
Urolithin A ameliorates schizophrenia-like behaviors and cognitive impairments in female rats by modulating NLRP3 signaling
Zhengyuan Huang, Guang‐Hui Chen, Zhongyu Ren, et al.
International Immunopharmacology (2025) Vol. 151, pp. 114336-114336
Closed Access | Times Cited: 1
Neuroimaging epicenters as potential sites of onset of the neuroanatomical pathology in schizophrenia
Yuchao Jiang, Lena Palaniyappan, Cheng Luo, et al.
Science Advances (2024) Vol. 10, Iss. 24
Open Access | Times Cited: 4
Clinical Characteristics and Prognostic Clinical Factors of Anti-Gamma-Aminobutyric Acid-B Receptor (Gabab-R) Encephalitis in Turkiye: A Multicenter Study
Rabia Gökçen Gözübatık Çelik, Betül Baykan, Ahmed Serkan Emekli, et al.
(2025)
Closed Access
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis
Paul M. Burkat
Journal of Psychopharmacology (2025)
Closed Access
A novel supramolecular nanodrugs for improving the cognitive function of schizophrenia by protecting active lactone of arecoline
Xianhua Zhang, Kaining Zhang, Ke-Jun Liu, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117845-117845
Closed Access
Research Progress on MECT Combined with Second-Generation Antipsychotic Drugs in the Treatment of Schizophrenia
堃 杨
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 871-877
Closed Access
Imaging Biomarker Studies of Antipsychotic-Naïve First-Episode Schizophrenia in China: Progress and Future Directions
Wenjing Zhang, Changjian Qiu, Su Lui
Schizophrenia Bulletin (2025)
Closed Access
Discharge Against Medical Advice Among Schizophrenia Patients in Germany: A Multicenter Cross-Sectional Study
Karel Kostev, Ira Rodemer, André Hajek, et al.
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 196-196
Open Access
The Role of Dopamine in Neurological, Psychiatric, and Metabolic Disorders and Cancer: A Complex Web of Interactions
Luisa Speranza, Maria Concetta Miniaci, Floriana Volpicelli
Biomedicines (2025) Vol. 13, Iss. 2, pp. 492-492
Open Access
Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
Martin Osugo, Matthew B. Wall, Pierluigi Selvaggi, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Single-subject network analysis of FDOPA PET in Parkinson’s disease and Psychosis spectrum
M. Severino
Research Square (Research Square) (2025)
Closed Access
The Relationship of glutamate signaling to cannabis use and schizophrenia
Margaret Niznikiewicz, Alexander P. Lin, Lynn E. DeLisi
Current Opinion in Psychiatry (2025)
Closed Access
Urolithin A alleviates schizophrenic-like behaviors and cognitive impairment in rats through modulation of neuroinflammation, neurogenesis, and synaptic plasticity
Zhengyuan Huang, Zhongyu Ren, Sanwang Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Brain functional connectivity associated with cognitive deficits in younger patients at first episode of schizophrenia
Na Liu, Lihua Xu, Xiaofeng Guan, et al.
Schizophrenia Research Cognition (2025) Vol. 41, pp. 100359-100359
Closed Access
Spurious autobiographical memories of psychosis: a dopamine-gated neuroplasticity account for relapse and treatment-resistant psychosis
Eric Chen, Stephanie Ming Yin Wong, Masatomo So, et al.
Psychological Medicine (2025) Vol. 55
Closed Access
The conundrum of the connection between severe psychiatric disorders and dementia
Antônio Lúcio Teixeira, Gabriel A. de Erausquin, Rene L. Olvera
Dementia & Neuropsychologia (2025) Vol. 19
Open Access
Meta-analysis of structural and functional brain abnormalities in early-onset schizophrenia
Lu Wang, Ruishan Liu, Juan Liao, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Unraveling the role of the renin-angiotensin system in severe mental illnesses: An insight into psychopathology and cognitive deficits
Aline Silva de Miranda, Danielle Macêdo, Lia Lira Olivier Sanders, et al.
Cellular Signalling (2024), pp. 111429-111429
Closed Access | Times Cited: 3
What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia
Christoph U. Correll, Massimo Tusconi, Mauro Giovanni Carta, et al.
Biomolecules (2024) Vol. 14, Iss. 8, pp. 906-906
Open Access | Times Cited: 2
IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia.
Brian Dean
Pharmacological Research (2024) Vol. 210, pp. 107510-107510
Open Access | Times Cited: 2
Inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia
Risako Fujikawa, Jun Yamada, Shoichiro Maeda, et al.
Journal of Neurochemistry (2024)
Closed Access | Times Cited: 1
Aberrant glycosylation in schizophrenia: insights into pathophysiological mechanisms and therapeutic potentials
Yanchen Feng, Lu Sun, Xue Dang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats
Charalampos Brakatselos, Alexia Polissidis, George Ntoulas, et al.
Neuropsychopharmacology (2024) Vol. 50, Iss. 2, pp. 388-400
Closed Access | Times Cited: 1
Hearing problems in humans and mouse models with rare copy number variants associated with schizophrenia: a scoping review protocol
Stephen Murtough, Daniele Panconesi, Lu Chen, et al.
Wellcome Open Research (2024) Vol. 9, pp. 546-546
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top